OncoMatch/Clinical Trials/NCT03832361
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
Is NCT03832361 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies IMGN853 for endometrial cancer.
Treatment: IMGN853 — The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Biomarker criteria
Required: FOLR1 FRα-positive tumor expression as defined in the protocol
FRα-positive tumor expression as defined in the protocol
Disease stage
Grade: Grade 2Grade 3
Have measurable disease; Grade 2 or Grade 3 endometrial adenocarcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: folate receptor-targeting investigational agents
Lab requirements
Blood counts
adequate hematologic function as defined in the protocol
Kidney function
adequate kidney function as defined in the protocol
Liver function
adequate liver function as defined in the protocol
Patients must have adequate hematologic, liver and kidney function as defined in the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Smilow Cancer Hospital at Yale New Haven · New Haven, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify